Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAP2 | P11137 | 1/20 | 0.44 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.43 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30043529 | 0.74 | ALDH1A1 (0.59) | HSD17B10KDM4EMAPTGAAALOX15 | |
| SCHEMBL23498248 | 0.74 | ALDH1A1 (0.59) | HSD17B10KDM4EMAPTGAAALOX15 | |
| SCHEMBL28962399 | 0.73 | POLB (0.46) | KDM4EGAAALDH1A1HPGDMAP2 | |
| SCHEMBL8523338 | 0.72 | ALDH1A1 (0.54) | HSD17B10KDM4EMAPTGAAALOX15 | |
| SCHEMBL22450909 | 0.71 | MAP2 (0.52) | MAPTGAAALOX15HPGDMAP2 | |
| SCHEMBL6769146 | 0.69 | ALOX5 (0.54) | ALOX15SIRT1PPARG | |
| SCHEMBL31025931 | 0.68 | GPR17 (0.57) | HSD17B10KDM4EMAPTGAAALOX15 | |
| SCHEMBL27344324 | 0.68 | KDM4E (0.56) | HSD17B10KDM4EMAPTGAAALOX15 | |
| SCHEMBL1720869 | 0.67 | HSD17B10 (0.55) | HSD17B10KDM4EMAPTGAAALOX15 | |
| SCHEMBL38663581 | 0.65 | PTGS2 (0.47) | HSD17B10KDM4EMAPTGAAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6716605-B2 | Indole derivatives having an antiviral activity | SHIONOGI & CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-20030181499-A1 | Indole derivatives having an antiviral activity | FUJISHITA TOSHIO (JP) | 2003-09-25 | — | — | US | disclosed |
| US-6506787-B2 | Aids therapy | SHIONOGI & CO., LTD. (JP) | 2003-01-14 | — | — | US | disclosed |
| US-20020019434-A1 | Indole derivatives having an antiviral activity | FUJISHITA TOSHIO (JP) | 2002-02-14 | — | — | US | disclosed |
| US-6333323-B1 | AS ANTI-HUMAN IMMUNODEFICIENCY VIRUS (HIV) DRUGS | SHIONOGI & CO., LTD. (JP) | 2001-12-25 | — | — | US | disclosed |
| EP-1069111-A1 | INDOLE DERIVATIVES WITH ANTIVIRAL ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019434-A1 | Indole derivatives having an antiviral activity | IDO1, IDO2, RCOR1 | HSD17B10 684/4885KDM4E 370/4885MAPT 4082/4885 |
| US-20030181499-A1 | Indole derivatives having an antiviral activity | IDO1, RCOR1, IDO2 | HSD17B10 660/4885KDM4E 287/4885MAPT 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.